Design Therapeutics develops GeneTAC small molecule drug candidates for inherited diseases caused by repeated gene sequences. It last closed at $9.02 on Nov 20, down 3.22% on the day. The next earnings report for DSGN is expected around Mon, Mar 8, 2027, after the close. For the quarter ended Sep 2026, DSGN reported EPS of -$0.32 on revenue of $0. Over its last 8 reports the stock moved an average of 7.5% the session after earnings.
AI Auto Pilots
Is DSGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DSGN.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on DSGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
DSGN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 14% below its 20 day and 24% below its 50 day average. It is 35% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $8.80, and the nearest resistance the Pivot at $9.18.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.0%/day
Key levels
$17.2552 week high+91.2%
$12.64100 day average+40.1%
$12.17200 day average+34.9%
$11.1450 day average+23.5%
$11.00Swing high (Nov 11)+22.0%
$10.2820 day average+14.0%
$9.41Pivot R1+4.3%
$9.18Pivot+1.8%
$9.02Last close
$8.80Pivot S1−2.4%
$7.8152 week low−13.4%
Indicators
RSI (14)
32.82
Weak, oversold below 30
Neutral
MACD
-0.49
Below its signal line
Bearish
Stochastic
3.8
Near the bottom of its range
Oversold
ADX (14)
19.3
No clear trend
Williams %R
-97.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-193.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−11.7%
Change over 10 sessions
Bearish
ATR (14)
$0.63
Typical daily range, 7.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 17.9%/day
Key levels
$17.2552 week high+91.2%
$12.64100 day average+40.1%
$12.17200 day average+34.9%
$11.1450 day average+23.5%
$11.00Swing high (Nov 11)+22.0%
$10.2820 day average+14.0%
$9.41Pivot R1+4.3%
$9.18Pivot+1.8%
$9.02Last close
$8.80Pivot S1−2.4%
$7.8152 week low−13.4%
Indicators
RSI (14)
35.82
Weak, oversold below 30
Neutral
MACD
-0.57
Below its signal line
Bearish
Stochastic
9.0
Near the bottom of its range
Oversold
ADX (14)
25.4
Trending down
Williams %R
-99.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-132.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−38.4%
Change over 10 sessions
Bearish
ATR (14)
$1.62
Typical daily range, 17.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for DSGN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how DSGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow DSGN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for DSGNHow many large options trades hit DSGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in DSGN in the last 90 days.
From SEC Form 4 filings by DSGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DSGN is in one of them and how their past DSGN trades turned out.
Design Therapeutics is a biopharmaceutical company based in Carlsbad, California, that researches and develops GeneTAC molecules, a type of small molecule. These molecules are designed to target repeated DNA sequences that cause certain inherited diseases, and to adjust how genes are expressed in affected cells. The company's lead candidates are aimed at Friedreich ataxia, Fuchs endothelial corneal dystrophy and myotonic dystrophy type 1. Its candidates are still in development and are intended for patients with these inherited conditions.